The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Pediatric growth hormone deficiency (PGHD) is a genetic condition that affects your child’s physical development. Hormone replacement therapy can help promote growth, and a new injection now makes it ...
NEW YORK (Reuters Health) - Hormone replacement therapy after menopause may interfere with the accuracy of mammograms used to screen for breast cancer -- and the risk may be greater with hormones ...
For many women in the United States who encounter drenching night sweats, sudden hot flashes, debilitating exhaustion and ...